Cargando…
Nanotherapeutics for Treatment of Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a devastating and fatal chronic lung disease. While current pharmacotherapies have improved patient quality of life, PAH drugs suffer from limitations in the form of short-term pharmacokinetics, instability, and poor organ specificity. Traditionally, nanotech...
Autores principales: | Segura-Ibarra, Victor, Wu, Suhong, Hassan, Nida, Moran-Guerrero, Jose A., Ferrari, Mauro, Guha, Ashrith, Karmouty-Quintana, Harry, Blanco, Elvin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055049/ https://www.ncbi.nlm.nih.gov/pubmed/30061840 http://dx.doi.org/10.3389/fphys.2018.00890 |
Ejemplares similares
-
Editorial: Molecular Mechanisms in Pulmonary Hypertension and Right Ventricle Dysfunction
por: Karmouty-Quintana, Harry, et al.
Publicado: (2018) -
Switching-Off Adora2b in Vascular Smooth Muscle Cells Halts the Development of Pulmonary Hypertension
por: Mertens, Tinne C. J., et al.
Publicado: (2018) -
Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives
por: Collum, Scott D., et al.
Publicado: (2017) -
Insights and Advances in the Diagnosis, Treatment, and Management of
Pulmonary Hypertension
por: Guha, Ashrith, et al.
Publicado: (2021) -
Evaluation, Diagnosis, and Classification of Pulmonary
Hypertension
por: Sarah, Beshay, et al.
Publicado: (2021)